Inhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual Meeting

TAMPA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. (OTCQB: INTI) ("Inhibitor" or the "Company") today highlighted several important developments disclosed in its Quarterly Report on Form 10-Q filed August 14, 2026, and encouraged stockholders and other interested parties to review the filing for a more complete discussion of the Company’s progress. Recent progress includes a revised regulatory strategy for itraconazole in Basal Cell Carcinoma Nevus Syndrome ("BCCNS" or